Moderate

Alpha-1 antitrypsin deficiency

inherited emphysema · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Alpha-1 antitrypsin deficiency is an inherited cause of early-onset, basal-predominant emphysema and liver disease, classically in the ZZ phenotype. Testing is recommended in COPD/emphysema especially when early-onset, minimal smoking, basal distribution or positive family history.

Red flags

  • Rapid FEV1 decline in a young patient
  • Hepatic decompensation or hepatocellular carcinoma features
  • Haemoptysis / new mass (exclude cancer)
  • Severe hypoxaemia / cor pulmonale

Assessment

Differential diagnosis

  • Smoking-related COPD/emphysema
  • Bronchiectasis
  • Asthma
  • Other causes of panacinar emphysema
  • Chronic liver disease of other cause

Investigations

  • Serum alpha-1 antitrypsin level
  • Phenotyping/genotyping (e.g. PiZZ, PiSZ)
  • Spirometry with reversibility and gas transfer
  • HRCT chest (basal panacinar emphysema, bronchiectasis)
  • Liver function tests and liver assessment
  • Family screening and counselling

Management

  • Suspect in emphysema that is early-onset, basal, in non/light smokers or with family history
  • Measure serum alpha-1 antitrypsin level and confirm with phenotype/genotype
  • Assess lung involvement with spirometry, gas transfer and HRCT
  • Evaluate liver involvement with LFTs and imaging
  • Advise strict smoking avoidance and minimise occupational/environmental exposures
  • Treat airflow obstruction with standard inhaled COPD therapy and pulmonary rehabilitation
  • Vaccinate and manage exacerbations promptly
  • Consider intravenous alpha-1 antitrypsin augmentation therapy in selected patients with emphysema
  • Screen and counsel family members and offer genetic counselling
  • Refer advanced lung disease for transplant and monitor for liver complications

Drugs & doses

Alpha-1 antitrypsin augmentation: pooled human alpha-1 proteinase inhibitor 60 mg/kg IV once weekly (selected emphysema patients)
Standard inhaled therapy e.g. LABA-LAMA +/- ICS per phenotype
Smoking-cessation pharmacotherapy
Vaccination (influenza, pneumococcal, COVID-19, hepatitis for liver protection)

Disposition

Specialist respiratory / alpha-1 service; hepatology for liver disease; family screening and transplant assessment for advanced disease.

Complications & pitfalls

  • Progressive emphysema and respiratory failure
  • Cirrhosis and hepatocellular carcinoma
  • Bronchiectasis
  • Panniculitis and (rarely) vasculitis

Exam pearls

  • Smoking dramatically accelerates lung destruction — cessation is the single most important intervention
  • Emphysema is classically basal and panacinar, in contrast to upper-zone smoking emphysema
  • Augmentation therapy slows CT-measured emphysema progression but not all guidelines endorse it
  • Liver disease arises from polymer accumulation, independent of the lung disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.